YBL 031
Alternative Names: ACE18; CD20/ALiCE; YBL-031Latest Information Update: 28 Jun 2023
At a glance
- Originator Y-Biologics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported B-cell lymphoma
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in B-cell lymphoma in South Korea (Parenteral)
- 30 May 2019 Y Biologics plans in vivo studies in Cancer in 2019 (Company communication, May 2019)
- 30 May 2019 Y biologics completes a in vitro studies in Cancer in South Korea, prior May 2019 (Company communication, May 2019)